Avilar Therapeutics, Inc. — Form D
Avilar Therapeutics, Inc. of WALTHAM, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-12-17. The offering totals $60.0M, of which $20.3M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-12-17
- Form: D
- Accession: 0001836740-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $60.0M
- Amount sold: $20.3M
- Remaining: $39.7M
- Investors: 3
- Date of first sale: 2020-12-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-383553
Issuer
- Name: Avilar Therapeutics, Inc.
- CIK: 0001836740
- Entity type: Corporation
- Jurisdiction: MASSACHUSETTS
- Incorporated: 2020
- Address: 400 TOTTEN POND ROAD, WALTHAM, MA, 02451
- Phone: 617-475-8493
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| MILIND DESHPANDE | Executive Officer | WALTHAM, MA |
| Joshua Resnick | Director | New York, NY |
| David Neafus | Executive Officer | Walpole, MA |
| Paulina Hill | Director | Cambridge, MA |
| THERESA CAMERON | Director | WALTHAM, MA |
| MARTIN FREED | Director | WALTHAM, MA |
| STEPHANIE TOZZO | Executive Officer | WALTHAM, MA |
| PHIL GRAHAM | Executive Officer | WALTHAM, MA |
| MILIND DESHPANDE | Director | WALTHAM, MA |
| DANIEL GRAU | Director | WALTHAM, MA |
| DANIEL GRAU | Executive Officer | WALTHAM, MA |
| ADAM MUZIKANT | Executive Officer | WALTHAM, MA |
Other filings by this issuer (1)
More